Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
This is a non-randomised dose escalation and dose expansion trial. During the dose escalation phase of this trial, patients will be allocated sequentially to receive escalating doses of GDC-9545 up to the maximum tolerated dose (MTD) or maximum administered dose (MAD). In the dose expansion phase of the trial, patients will receive GDC-9545 at a dose that is less than or equal to the MTD/MAD along with the approved LHRH agonist and/or Palbociclib.